RVPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Reviva Pharmaceuticals Holdings Inc (RVPH) is not a good buy for a beginner investor with a long-term strategy at this time. The stock faces significant challenges, including financial instability, a bearish technical trend, and lack of positive catalysts. The absence of strong trading signals and recent analyst downgrades further support a cautious approach.
The technical indicators for RVPH are bearish. The moving averages (SMA_200 > SMA_20 > SMA_5) indicate a downward trend. The RSI is neutral at 29.093, and the MACD histogram, while positive, is contracting. The stock is trading near its S1 support level of 0.259, suggesting limited upside potential in the short term.
NULL identified. No recent news or events suggest a positive catalyst for the stock. The options data also does not indicate strong bullish sentiment.
The FDA's denial of the company's request to file an NDA without a second Phase 3 study is a major setback. Additionally, the company requires $60M-$75M to execute the second Phase 3 study, raising concerns about equity dilution. Analyst downgrades and reduced price targets further weigh on the stock.
In Q3 2025, the company's financial performance was poor. Revenue remained at 0, net income dropped by -52.06% YoY to -$4,010,773, and EPS fell by -76.00% YoY to -0.06. These figures indicate significant financial instability and lack of growth.
Roth Capital recently lowered the price target from $3 to $1.50 while maintaining a Buy rating. The downgrade reflects concerns about equity dilution and the need for additional funding to complete a second Phase 3 study. While the firm remains optimistic about brilaroxazine, the outlook is cautious.
